Skip to main content
Figure 5 | Lipids in Health and Disease

Figure 5

From: Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey

Figure 5

Original primary study design. In the original RCT, LDL-C was determined at Week 5 (Period I) to determine eligibility for Period II of the RCT. At Week 6, patients whose LDL-C levels remained elevated (≥100 and ≤160 mg/dL) had their treatment changed to a more intensive regimen during Period II. Period II baseline LDL-C was the average of Week 5 and 6 data. Lipids were also assessed at Week 11 and 12. Final period II values were the average of Week 11 and 12 data. For this analysis, only period I data were used. For further details of the study design, see Bays et al. 2013 [23]. ATV, atorvastatin; EZE, ezetimibe; RSV, rosuvastatin.

Back to article page